Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
September 2024
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Ann Rheum Dis 2024;0:1–8 DOI 10.1136/ard-2024-226142
Tur et al. demonstrated that CD19-targeting CAR T-cell therapy results in the depletion of B cells within deep tissues. The study highlights significant reductions in pathogenic B-cell populations, particularly in autoimmune diseases, after CD19-CAR T-cell administration.
Keywords:
April 2024
CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up
N Engl J Med 2024;390(8):687–700 DOI 10.1056/NEJMoa2308917
In this case series by Müller, et al., eight patients who received a CD19 CAR T-cell infusion achieved Definition of Remission in SLE (DORIS) remission, Lupus Low Disease Activity State and a SLEDAI 2K score of 0 at 6 months post-infusion. Long-term follow-up through 24 months showed that SLE disease activity remained absent
in all eight patients.
Keywords:
November 2022
Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus
Nat Med. 2022;28(10):2124–2132 doi: 10.1038/s41591-022-02017-5
Data suggest that CD19 chimeric antigen receptor (CAR) T cell transfer is feasible, tolerable and highly effective in patients with SLE.